Dermatomyositis
Conditions
Interventions
Qingying Huashi Group:Prednisone: Initial dose of 0.5-1.0 mg/kg/day, determined based on the severity of the condition by the investigator. Starting from week 4, the dose is gradually tapered accordin
Control Group:Prednisone: Initial dose of 0.5-1.0 mg/kg/day, determined based on the severity of the condition by the investigator. Starting from week 4, the dose is gradually tapered according to dis
Sponsors
Department of Rheumatology and Immunology The Second Affiliated Hospital of Zhejiang University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Conform to the 2017 EULAR/ACR classification criteria for dermatomyositis in adult and juvenile IIM; (2) Patients with heat-toxicity, blood-stasis, and dampness obstruction type DM; (3) Individuals aged between 18 and 65 years old.
Exclusion criteria
Exclusion criteria: (1) Patients with severe infections or malignant tumors; NYHA class III-IV heart failure patients; individuals with abnormal liver function not caused by DM (e.g., ALT/AST levels exceeding twice the upper limit of normal); patients with end-stage organ dysfunction; individuals with positive serological tests for HIV or other pathogenic organisms. (2) Pregnant or breastfeeding women; individuals with uncontrolled psychiatric conditions. (3) Patients with other rheumatologic conditions, such as rheumatoid arthritis, systemic lupus erythematosus, or Sjögren's syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Illness Score (TIS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscle enzyme spectrum;TCM Syndrome Score;Hormone Usage;Myositis Spectrum;Inflammatory markers (erythrocyte sedimentation rate, C-reactive protein);Health Assessment Questionnaire (HAQ);Complications occurrence; | — |
Countries
China
Contacts
Public ContactWeijie Wang
The Second Affiliated Hospital of Zhejiang University of Chinese Medicine
Outcome results
None listed